John Winters, MD
Hematology & Oncology · Westbrook, MENPI 1366648693
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $225,704 of the $341,331 with a category attached, or 66.1%. 50 manufacturers reported payments, led by Incyte Corporation at 26.4% of the total. Reporting peaked in 2019 at $123,298 and has fallen 99.1% since, to $1,103 in 2025. Among hematology & oncology clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $790.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$90K
- E.r. Squibb & Sons, L.L.C.$79K
- Bristol Myers Squibb$47K
- AstraZeneca$29K
- Dova Pharmaceuticals$27K
- Johnson & Johnson$13K
- plus $56K from 44 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$75,00422%
- Speaking & faculty fees$225,70466%
- Travel & lodging$31,1479%
- Food & beverage$9,2553%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$341,331 in reported general payments places this provider in the 95th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 307 | $5,422,212 |
| BrukinsaZanubrutinib | 168 | $2,563,710 |
| JakafiRuxolitinib Phosphate | 111 | $1,865,335 |
| PomalystPomalidomide | 82 | $1,834,150 |
| CalquenceAcalabrutinib Maleate | 124 | $1,650,700 |
| ImbruvicaIbrutinib | 91 | $1,463,271 |
| VenclextaVenetoclax | 78 | $824,455 |
| Lenalidomide | 50 | $622,245 |
| OjjaaraMomelotinib Dihydrochloride | 22 | $581,630 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 50 | $473,476 |
| XpovioSelinexor | 15 | $467,846 |
| ScemblixAsciminib Hydrochloride | 16 | $345,596 |
| BraftoviEncorafenib | 16 | $313,614 |
| MektoviBinimetinib | 16 | $204,984 |
| TazverikTazemetostat Hydrobromide | 11 | $193,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $47,415 | $5,584,740319 claims |
| Beigene USA, Inc.Brukinsa | $7,864 | $2,563,710168 claims |
| Incyte CorporationJakafi | $90,184 | $1,865,335111 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $78,655 | $1,834,15082 claims |
| AstraZenecaCalquence | $29,366 | $1,650,700124 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $8,191 | $1,463,27191 claims |
| AbbVieVenclexta | $2,665 | $824,45578 claims |
| GSKOjjaara | $1,962 | $581,63022 claims |
| NovartisScemblix, Gleevec | $136 | $461,22628 claims |
| AmgenKyprolis, Aranesp | $12 | $265,19351 claims |
| Ipsen Biopharmaceuticals, IncTazverik | $1,040 | $193,88711 claims |
| PfizerEliquis | $91 | $131,972123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Westbrook
- Matthew DuganWestbrook$577K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
- Tracey WeisbergWestbrook$31K
- Daniel RauschWestbrook$20K
- Patrick BolandWestbrook$20K
- Owen PickusWestbrook$1K
- Chiara BattelliWestbrook$929
- Helen RyanKennebunk$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.